Nkarta plans its comeback
The company puts its faith in a new lymphodepletion regimen to overcome mediocre early results with its lead Car-NK therapy.
The company puts its faith in a new lymphodepletion regimen to overcome mediocre early results with its lead Car-NK therapy.
